iTeos Therapeutics ITOS 深 沪
已收盘 08-29 16:00:00 美东时间
10.15
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 10.15
- 总市值 3.61亿
- 52周最高 17.63
- 市盈率 静 1.79
- 换手率 0.00%
- 52周最低 4.80
- 委 比 0.00%
- 总股本 3554.07万
- 历史最高 52.43
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.10
- 每 手 1
- 风险率 1.55%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多iTeos Therapeutics Announces Its Intention to Wind Down Operations
iTeos Therapeutics intends to wind down operations, focusing on exploring asset sales such as EOS-984, EOS-215, and a preclinical obesity program targeting ENT1 to deliver near-term value to shareholders.
05-28 12:30
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite fall...
2024-09-17 00:31
Market-Moving News for September 16th
NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrolizumab For Patients With Metastatic Melanoma Who Were Refractory To Or Had Relapsed On
2024-09-16 20:08
Reported Saturday, iTeos Therapeutics Announced Follow-Up Interim Data From GALAXIES Lung-201 Phase 2 Platform Study Sponsored By GSK, For Belrestotug+Dostarlimab Doublet In Previously Untreated, Unresectable, Locally Advanced Or Metastatic PD-L1 High Non-small Cell Lung Cancer
Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose.>30% cORR difference between belrestotug +
2024-09-16 16:47
